Lexicon Pharmaceuticals, Inc.
LXRX
$0.5339
$0.0020.38%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 1,417.37% | 6.25% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 1,417.37% | 6.25% | |||
| Cost of Revenue | 0.32% | 45.16% | |||
| Gross Profit | 102.58% | -49.12% | |||
| SG&A Expenses | -46.81% | 1.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -28.20% | 14.81% | |||
| Operating Income | 67.91% | -15.06% | |||
| Income Before Tax | 47.90% | -21.30% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 47.90% | -21.30% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 47.90% | -21.30% | |||
| EBIT | 67.91% | -15.06% | |||
| EBITDA | 68.05% | -15.13% | |||
| EPS Basic | 47.91% | -4.30% | |||
| Normalized Basic EPS | 66.90% | -4.38% | |||
| EPS Diluted | 47.91% | -4.30% | |||
| Normalized Diluted EPS | 66.90% | -4.38% | |||
| Average Basic Shares Outstanding | 0.00% | 16.30% | |||
| Average Diluted Shares Outstanding | 0.00% | 16.30% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||